Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.042 | 0.2 |
mRNA | BRD-K24690302 | CTRPv2 | pan-cancer | AAC | 0.051 | 0.2 |
mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | 0.047 | 0.2 |
mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.07 | 0.2 |
mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.049 | 0.2 |
mRNA | SZ4TA2 | CTRPv2 | pan-cancer | AAC | -0.075 | 0.2 |
mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.051 | 0.2 |
mRNA | Ko-143 | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
mRNA | AZD8055 | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |
mRNA | AZD-7545 | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |